Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st Qtr Business Results
August 29, 2005
- Caiapo Launched in Australia, New Zealand
August 29, 2005
- All-case PMS Completed for Remicade; Tanabe to Gear Up Promotion
August 22, 2005
- Osaka Gov't Brings Lawsuits Demanding Payment of Copayments
August 22, 2005
- Taisho to Launch Switch-OTC Version of Novartis' Zaditen
August 22, 2005
- Uncollected Medical Fees - Why Don't Patients Pay?
August 22, 2005
- Bushu Pharm. to Start Independent PR Activities
August 22, 2005
- Approval of 5 Anticancer Agents Discussed
August 22, 2005
- BUSINESS NEWS IN BRIEF
August 22, 2005
- Nippon Chemiphar Announces New 3-Year Management Plan
August 22, 2005
- More than 400 Medical Institutions Issue GE Name Prescriptions
August 22, 2005
- MediciNova Starts PII Trial of Ibudilast for MS
August 22, 2005
- Burgeoning Clinical Trial Business in China
August 22, 2005
- 1st Qtr Business Results
August 22, 2005
- NEW PRODUCTS
August 22, 2005
- Associations Petition for Rapid Increase in Review Staff
August 22, 2005
- Olympus, Terumo to Develop New Medical Devices Based on Capital Alliance
August 22, 2005
- SELF-MEDICATION
August 22, 2005
- Retirees Drove Growth in Medical Expenditure in FY2004: Survey
August 22, 2005
- Council Calls for More Screening of Hepatitis C
August 22, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…